Even before COVID-19 set off a global tsunami of anxiety and depression, psychedelic drugs were already showing exciting promise for treating these and other intractable mental health conditions.
Compass Pathway’s recent raise of $80M to expand research into the clinical uses of psilocybin only affirms that no coronavirus is going to dampen efforts to make these treatments legal and widely accessible. If anything, the need for an effective answer to COVID-era angst makes this work even more urgent.
Especially for Baby Boomers and their elders, developments in the psychedelic space are worthwhile following, particularly because of their potential to radically improve quality of life, up to its inevitable end. (Read more on Forbes.com)
Leave a Reply